Shawn Tomasello
CIK: 0001617239
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jun 17, 2026FDMT
4D Molecular Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
50K shares- - Jun 9, 2026CABA
Cabaletta Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares- - Jan 21, 2026CABA
Cabaletta Bio, Inc.
Purchase(P)Indirect22.7K shares at avg. $2.21$50K - Jun 17, 2025FDMT
4D Molecular Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
22.5K shares- - Jun 9, 2025CABA
Cabaletta Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares- - May 19, 2025CABA
Cabaletta Bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
44K shares- - May 19, 2025CABA
Cabaletta Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
44K shares- - May 19, 2025CABA
Cabaletta Bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
22K shares- - May 19, 2025CABA
Cabaletta Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  FDMT 4D Molecular Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Jun 9, 2026 |  CABA Cabaletta Bio, Inc. | Award(A) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| Jan 21, 2026 | CABA Cabaletta Bio, Inc. | Purchase(P) | 22,725 | $2.21 | $50,322 | Indirect |
| Jun 17, 2025 | FDMT 4D Molecular Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 22,500 | - | - | Direct |
| Jun 9, 2025 | CABA Cabaletta Bio, Inc. | Award(A) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 44,000 | - | - | Direct |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | Award(A) Stock Option (Right to Buy) | 44,000 | - | - | Direct |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | Award(A) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
1-9 of 9 transactions
About Tomasello Shawn
Tomasello Shawn (SEC CIK 0001617239) files insider reports with the SEC as Director of 4D Molecular Therapeutics, Inc. (FDMT) and Director of Cabaletta Bio, Inc. (CABA).
Signal8 holds 6 ownership filings by Tomasello Shawn, all Form 4s, filed between May 19, 2025 and Jun 18, 2026. Those filings report 9 transactions, from May 19, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Tomasello Shawn's filings is in PHILADELPHIA, PA.
Recent filings by Tomasello Shawn
- Jun 17, 2026: Grant or award of FDMT derivative securities (Form 4, code A).
- Jun 9, 2026: Grant or award of CABA derivative securities (Form 4, code A).
- Jan 21, 2026: Open-market purchase of CABA shares (Form 4, code P).
- Jun 17, 2025: Grant or award of FDMT derivative securities (Form 4, code A).
- Jun 9, 2025: Grant or award of CABA derivative securities (Form 4, code A).
Other insiders filing for 4D Molecular Therapeutics, Inc. (FDMT)
- Bizily Scott, Chief Legal Officer
- Kirn David
- THEUER CHARLES, Director
- Miller-Rich Nancy, Director
- GRAY SUSANNAH, Director
- MILLIGAN JOHN F, Director